Skip to main content
. 2006 Nov 7;103(46):17408–17413. doi: 10.1073/pnas.0608372103

Fig. 4.

Fig. 4.

Tumor retention and efficacy in MM xenograft models. (A) Selective tumor retention of IPI-504 in RPMI-8226 tumor-bearing mice after i.v. administration of 50 mg/kg IPI-504. RPMI-8226 tumor-bearing mice were administered with test article via the tail vain, and tumor samples were collected at selected time points. Tumor samples were homogenized, and the homogenate supernatants were analyzed by online extraction LC-MS/MS. (B) In vivo efficacy of IPI-504 in an RPMI-8226 xenograft model as a single agent and in combination with bortezomib. Tumor-bearing mice received either (i) IPI-504 and bortezomib vehicle (♦), (ii) IPI-504 at 100 mg/kg (300 mg/m2), twice weekly (▴), (iii) bortezomib 0.3 mg/kg (0.9 mg/m2), twice weekly (○), or (iv) IPI-504 at 75 mg/kg (225 mg/m2) and bortezomib at 0.3 mg/kg (0.9 mg/m2), twice weekly (■), and tumor dimensions were measured twice weekly, as well as λ light chain concentrations 4 h after the last dose. (Inset) Point A, IPI-504 75 mg/kg and bortezomib 0.3 mg/kg; point B, bortezomib 0.3 mg/kg; point C, IPI-504 100 mg/kg; and point D, vehicle).